The heartburn drug faced a safety review when reports emerged that ranitidine (the drug name for Zantac) contained NDMA, a possible carcinogen.
Pharmaceutical companies like GSK, Sanofi and Haleon saw a sharp sell-off of their shares in US markets over fears of potential litigation charges by US authorities over the heartburn drug Zantac. Legal proceedings are expected to start on August 22, even as issues over the drugs have been there since 2018-19.
The drug was developed by GSK in the 1980s. It was initially a prescription drug before it was made available over-the-counter. In 2019, the drug faced a safety review when reports emerged that ranitidine (the drug name for Zantac) contained NDMA, a possible carcinogen. As the patent over the drug expired in 1997, the drug was taken up by multiple manufacturers.
By 2020, the US Food and Drug Administration and the European Medicines Agency had requested all versions of the drug to be pulled out of markets. The drug remains available in India with no particular directives from the Central Drugs Standard Control Organisation (CDSCO), though GSK has stopped selling the drug in the country even as other pharma companies still sell the drug.